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Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an
Inhibitor of Sp1-Mediated Survivin Transcription, Induces
Radiosensitization in Non-small Cell Lung Carcinoma
Yunguang Sun, PhD, Nicholas J. Giacalone, BS, and Bo Lu, MD, PhD
Introduction: Survivin, an inhibitor of apoptosis protein and key
regulator of mitosis, is up-regulated in a variety of cancers and is
often associated with a worse prognosis. Terameprocol down-regu-
lates the Sp1-mediated transcription of survivin and Cdk1, which is
important for cell cycle progression and many other proteins. Sur-
vivin inhibition has previously been shown to result in the induction
of apoptosis and radiosensitization.
Methods: This study examined the effects of terameprocol admin-
istration on survivin transcription and expression in HCC2429 and
H460 lung cancer cells. We also examined the combined effects of
radiation and terameprocol on apoptosis and radiosensitivity.
Results: Using immunoblot analysis and luciferase assays, we
confirmed that terameprocol decreases survivin transcription and
protein expression. Ultimately, however, decreases in survivin ex-
pression failed to correlate with an increase in apoptosis. Nonethe-
less, clonogenic assay revealed that terameprocol induces increased
radiosensitization in HCC2429 (dose enhancement ratio 1.26, p
0.019) and H460 (dose enhancement ratio  1.18, p  0.001) cells.
Additionally, the data show no effect of terameprocol on cell cycle
in either HCC2429 or H460 cells.
Conclusions: Terameprocol significantly enhances the sensitivity of
non-small cell lung carcinoma cell lines to radiation therapy, al-
though the mechanism of action remains unclear. Further study is
warranted to assess the potential of terameprocol as an agent that
may enhance the therapeutic ratio of radiotherapy in lung cancer.
Key Words: Non-small cell lung carcinoma, Terameprocol, Radio-
sensitization, Survivin.
(J Thorac Oncol. 2011;6: 8–14)
Lung cancer continues to be the leading cause of cancermortality in the United States.1 Approximately 80% of all
lung cancer cases are non-small cell lung carcinoma (NSCLC), and
the 5-year overall survival is 15%. Radiation therapy plays an
integral role in the multimodality treatment approach of
locally advanced NSCLC. The efficacy of radiotherapy, how-
ever, is hindered partly by defects in the apoptotic machinery
of cancer cells. Mechanisms of apoptosis, therefore, have
become promising targets for the development of novel
therapeutic agents that enhance radiation-induced cell death
and lead to improved clinical outcomes.2
Apoptosis, or programmed cell death, involves the
release of caspase proteases from the mitochondria and is
regulated by members of the Bcl-2 proteins family and the
inhibitor of apoptosis proteins (IAPs) family.3 At 16.5-kDa,
survivin is the smallest member of the IAP family and has
been shown to play critical roles in inhibiting apoptosis and
promoting angiogenesis and cellular proliferation.4 Survivin
is selectively expressed at G2/M and localizes to the mitotic
spindle, playing an integral role in several steps of cell
division including centrosome functions and spindle forma-
tion.5 Inhibition of apoptosis may involve a collection of
survivin segregated in mitochondria and subsequently re-
leased into the cytoplasm in response to apoptotic stimuli.6
Similar to most members of the IAP family, survivin does not
directly inhibit caspases. Survivin’s effects on cell death
inhibition seem to be mediated by interactions with other
proteins, including another IAP, X-linked IAP (XIAP),6,7 and
the hepatitis B X-interacting protein.8 The relative balance of
proapoptotic factors such as Bax, Bak, and Bid and antiapop-
totic factors such as survivin, Bcl-2, and Bcl-XL regulates the
level of apoptosis. Thus, overexpression of antiapoptotic
survivin promotes cell survival in cancer cells. This also
affects the ability of cancer cells to avoid treatment-induced
apoptosis and contributes to therapeutic resistance to various
agents, including radiation.
Indeed, overexpression of survivin has been noted in
virtually all cancers, including lung,9,10 breast,11 colon,12
pancreas,13 and hematological malignancies,14–16 whereas
survivin expression in most terminally differentiated tissues
is undetectable.17 Additionally, survivin has been shown to
confer resistance to several anticancer agents,18–20 and high
expression of survivin correlates with poorer prognosis in a
variety of cancers, including NSCLC.9,21 Given its impor-
tance in cancer, elucidating how survivin is implicated in
NSCLC apoptosis may promote the development of novel
therapeutic strategies to sensitize NSCLC tumors to treatment
and improve clinical outcome.
In this study, we investigated the role for survivin
inhibition in NSCLC radiosensitization. We tested the use of
terameprocol (tetra-O-methyl nordihydroguaiaretic acid, for-
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merly known as EM-1421 and M4N), a DNA major groove
binder that was previously shown to inhibit survivin expres-
sion and induce apoptosis in cancer cells with high levels of
survivin in vitro and in vivo,22,23 as a radiosensitizing agent in
NSCLC. The lignan terameprocol targets and inhibits the
Sp1-mediated transactivation of survivin transcription. The
anticancer activity of terameprocol also stems from its ability
to inhibit Sp1-mediated Cdk1 (Cdc2) expression, another
protein frequently up-regulated in human cancer that is in-
volved in the phosphorylation of several proteins involved in
the G2/M transition.22,24 Several studies have already shown
that inhibition of survivin enhances apoptosis and sensitizes
cancer cells to anticancer therapies.25–28 YM155, a small
molecule survivin suppressant, has been shown to enhance
apoptosis and tumor regression in hormone-refractory pros-
tate tumors in vivo29 and to radiosensitize NSCLC cell lines
in vitro.30 To date, however, no studies have shown the effect
of terameprocol on sensitizing NSCLC to radiation. Our
results suggest that there is value in using terameprocol to
sensitize NSCLC to radiation, although this effect is likely
independent of survivin inhibition.
MATERIALS AND METHODS
Cell Culture and Reagents
Human NSCLC cells were obtained from the following
sources: NCI-H460 (H460) from the American Type Culture
Collection (Manassas, VA), and HCC2429 was kindly pro-
vided by Dr. Thao P. Dang (Vanderbilt University, Nashville,
TN). All cells were cultured in RPMI 1640 (Invitrogen,
Carlsbad, CA), supplemented with 10% fetal bovine serum
(Invitrogen) and 1% penicillin-streptomycin (Invitrogen) at
37°C and humidified 5% CO2. Terameprocol (tetra-O-methyl
nordihydroguaiaretic acid) was provided by Erimos Pharma-
ceuticals (Raleigh, NC). A stock solution was prepared in
100% dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO)
and stored at 20°C. The drug was diluted in fresh media
before each experiment.
Plasmids, Transfection, and Dual-Luciferase Assay
The pLuc and pLuc2931 plasmids were obtained from
Health Research, Inc. (Buffalo, NY). The pLuc2931 plasmid
contains 2931 base pairs of human survivin promoter,
whereas pLuc is a nonpromoter control. HCC2429 and H460
cells were plated at 2 104/well in a 24-well format, and 200
ng total DNA was transfected with 0.6 L Lipofectamine
2000 (Invitrogen), and the pRL Renilla-Thymidine kinase
reporter vector (Promega, Madison, WI) was used as a
transfection efficiency control. Luciferase activity was de-
tected by the Dual-Luciferase Assay System (Promega).
Immunoblotting
H460 and HCC2429 cells were washed twice with
ice-cold phosphate-buffered saline (PBS) and then lysed in
M-PER mammalian lysis buffer (Thermo Scientific, Waltham,
MA). The protein concentration of lysates was quantified
using the Bradford reagent (Bio-Rad, Hercules, CA), and
equal amounts of protein were loaded into each well and
separated by 15% sodium dodecyl sulfate polyacrylamide gel
electrophoresis. The separated proteins were transferred to a
nitrocellulose membrane (Perkin Elmer Life Science), which
was then exposed to 5% nonfat dried milk in 0.1% tris-
buffered saline Tween 20 for 1 hour at room temperature. The
blots were then incubated overnight at 4°C with the following
rabbit polyclonal antibodies: anti-survivin (1:2000 dilution;
R&D Systems, Minneapolis, MN); anti-cellular inhibitor of
apoptosis protein 1 (cIAP1) and anti-cellular inhibitor of
apoptosis protein 2 (cIAP2) (1:1000 dilution; MBL Interna-
tional, Woburn, MA); anti-XIAP, anti-Bcl-2, anti-Bcl-XL,
anti-Mcl-1 (1:1000 dilution; Cell Signaling Technology,
Danvers, MA); anti-Bax and anti-Bak (1:1000 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA); anti-caspase-3 (1:
1000 dilution; Cell Signaling Technology); anti-tubulin (1:
1000 dilution; Sigma); and anti--actin (1:8000 dilution;
Sigma). The membranes were then washed with tris-buffered
saline Tween 20 before incubation for 1 hour at room tem-
perature with horseradish peroxidase-conjugated goat antirab-
bit IgG secondary (1:5000; Santa Cruz Biotechnology). Im-
mune complexes were finally detected with enhanced
chemiluminescence reagents (Perkin-Elmer Life Science,
Waltham, MA).
In Vitro Clonogenic Assay
H460 and HCC2429 cells in 100-mm dishes were
harvested by exposure to trypsin (0.05% trypsin-ethylenedia-
minetetraacetic acid (EDTA), GIBCO, Grand Island, NY)
and counted. They were diluted serially to appropriate den-
sities and plated in triplicate in 60-mm dish containing 5 ml
of complete medium in the presence of 10 M terameprocol
or DMSO (final DMSO concentration of 0.1%; we confirmed
that this DMSO concentration did not affect the proliferation
of NSCLC cell lines). After incubation for 24 hours, the cells
were irradiated using a 137Cs irradiator (J.L. Shepherd and
Associates, Glendale, CA) at room temperature. The dose
rate was 1.8 Gy/min, and the dose range was 0 to 6 Gy.
Fourty-eight hours after irradiation, the cells were washed
with PBS, cultured in drug-free medium for 7 to 8 days, fixed
with 70% ethanol, and stained with 0.5% crystal violet
(Sigma). After staining, colonies were counted using a cutoff
of 50 viable cells. Surviving fraction was calculated as (mean
colony counts)/(cells inoculated)  (plating efficiency),
where plating efficiency was defined as (mean colony
counts)/(cells inoculated for nonirradiated controls). The ra-
diation dose enhancement ratio (DER) was calculated as the
dose (Gy) of radiation plus vehicle (DMSO) divided by the
dose (Gy) for radiation plus terameprocol (normalized for
terameprocol toxicity) necessary for a surviving fraction of
0.2. Experiments were conducted in triplicate, and mean,
standard deviation (SD), and p values (using Student’s t test)
were calculated.
Cell Cycle Analysis
Cells (2 106) were seeded in 100-mm dishes and treated
with DMSO, 10 M terameprocol, or 30 M terameprocol for
24 hours or 48 hours. The cells were then collected by
trypsinization (0.05% trypsin-EDTA, GIBCO), fixed with 70%
ethanol, and stored overnight at 20°C. Cells were then col-
lected by centrifugation and were resuspended in 1 ml of PBS
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with 40 g/ml DNase-free RNase A (Clontech Laboratories,
Inc., Mountain View, CA) and then incubated at 37°C for 30
minutes. Propidium iodide (50 g/ml) (Sigma) was then added,
and the cells were incubated at room temperature for 5 minutes.
Cell number in each phase of the cell cycle was determined and
calculated as a percentage of the total cell population. The
analysis was repeated three times using flow cytometry, and the
mean and SD were calculated and graphed.
Statistic Analysis
The data presented represent mean SD for all measured
biologic parameters. Student’s t test was used to determine the
significance between groups. Statistical analysis was performed
with Microsoft Excel. Significance was defined at the level of
p  0.05. Asterisks (*) represent statistical significance.
RESULTS
Terameprocol Induces Transcriptional Down-
Regulation and Decreased Expression of Survivin
Protein in HCC2429 and H460 NSCLC Cells
To evaluate the capacity of terameprocol to down-
regulate survivin, HCC2429 and H460 lung cancer cells were
transfected with pLuc2931, a luciferase reporter under the
control of a human survivin promoter fragment, and pLuc
control. As shown in Figure 1A, survivin transcription was
down-regulated at 24 hours and significantly so after 48 hours
of treatment with 10 M terameprocol in HCC2429 cells
(p  0.05). Treatment with 10 M terameprocol in H460 lung
cancer cells resulted in significant down-regulation of survivin
transcription at both 24 (p  0.05) and 48 hours (p  0.05).
To further examine survivin expression after treatment
with terameprocol in vitro, levels of survivin were determined
by Western blot analysis (Figure 1B). Analysis revealed that
baseline expression of survivin protein was comparable in the
two cell lines. As expected, HCC2429 and H460 cells exhibit
inhibition of survivin expression in both a time- and dose-
dependent manner after terameprocol treatment.
Decreased Levels of Survivin Expression do
Not Necessarily Correspond with Increased
Levels of Apoptosis
To test the relationship between survivin expression
and apoptosis, HCC2429 and H460 cells were treated with
radiation (3Gy) for 0, 24, 48, and 72 hours. Immunoblotting
revealed increased levels of survivin, with a decline in sur-
vivin expression 72 hours after radiation in each cell line
(Figure 2A). Notably, cleaved caspase-3 levels increased in
HCC2429 NSCLC cells after 48 and 72 hours. In contrast, no
cleaved caspase-3 was observed in H460 cells, even at 72
hours when survivin expression was decreased. These data
demonstrate that H460 cells are apoptosis-resistant relative to
HCC2429 cells.
Differential Expression of Apoptotic Proteins in
HCC2429 and H460 Lung Cancer Cell Lines
Protein expression levels of members of the Bcl-2
protein family and IAP family in lung cancer cell lines were
determined by Western blot analysis, as shown in Figure 2B.
Both HCC2429 and H4260 NSCLC cells express high, com-
parable levels of survivin. H460 cells, an apoptotic-resistant
cell line, were found to express higher levels of Bcl-2,
Bcl-XL, and Mcl-1 compared with HCC2429 cells. In con-
trast, the proapoptotic proteins Bax and Bak were expressed
in greater quantities in HCC2429 cells relative to H460 lung
cancer cells. Notably, expression of cIAP-1 and cIAP-2 was
FIGURE 1. Terameprocol down-
regulates survivin transciption and
protein expression in HCC2429
and H460 cells. A, HCC2429 and
H460 cells were transfected with
200 ng pLuc2931 or pLuc control
and 0.6 L lipofectamine 2000.
Luciferase activity was detected 24
and 48 hours posttransfection and
plotted. The luciferase assay was
performed in triplicate, and error
bar is shown as mean  standard
deviation (SD). B, Immunoblotting
was used to determine survivin ex-
pression in HCC2429 and H460
cell lysates 24 and 48 hours after 0,
10, or 30 M terameprocol treat-
ment. Actin was probed to demon-
strate equal loading.
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greater in HCC2429 cells, whereas XIAP exhibited slightly
higher expression in H460 cells. These findings suggest
differential regulation in the expression of Bcl-2 family and
IAP family member proteins in these two lung cancer cell
lines and may help explain the different levels of apoptosis
exhibited in HCC2429 and H460 cells in Figure 2A.
Terameprocol Enhances Radiosensitivity in
Both HCC2429 and H460 Lung Cancer Cells
We used in vitro clonogenic assays to determine the
effect of terameprocol on the radiosensitivity of HCC2429
and H460 cell lines (Figure 3A). Both cell lines were treated
with 10 M terameprocol or DMSO control and irradiated
with 0 to 6 Gy. Clonogenic survival assay demonstrates a
significant decrease in cell survival in both HCC2429 and
H460 cells, with DERs of 1.26 (p  0.019) and 1.18 (p 
0.001), respectively, when compared with control.
Administration of Terameprocol and Radiation
Results in Increased Apoptosis in HCC2429
Cells but Not H460 Cells
To investigate the effects of survivin inhibition on
radiation-induced apoptosis, HCC2429 and H460 cells were
pretreated with 10 M terameprocol for 24 hours followed by
administration of 3 Gy radiation and subsequent incubation
for 48 hours (Figure 3B). Western blot analysis showed that
in both HCC2429 and H460 cells, the expression of survivin
in nonirradiated cells was decreased after terameprocol treat-
ment, when compared with DMSO controls. Nevertheless,
after administration of radiation HCC2429 cells exhibited
increased levels of survivin in terameprocol-treated cells. In
contrast, irradiated H460 cells pretreated with terameprocol
saw slightly decreased expression of survivin. Despite the
increase in survivin expression, HCC2429 cells treated with
radiation and terameprocol exhibited a synergistic increase in
apoptosis relative to radiation alone, whereas no cleaved
caspase-3 was detected in H460 cells under any conditions.
Although terameprocol seems to be more effective at decreas-
ing survivin expression in H460 cells, it is not sufficient to
produce apoptosis in this relatively apoptosis-resistant cell
line. Thus, these data suggest that even though terameprocol
does not increase levels of apoptosis in H460 cells, the drug
is sufficient for radiosensitization of this cell line (Figure 3A),
suggesting an important role for terameprocol in radiation-
induced cell death in these cells.
Terameprocol has No Effect on Cell Cycle in
Either HCC2429 or H460 Lung Cancer Cells
Survivin expression is increased in actively dividing
cells and is expressed predominately during the G2/M tran-
sition, when it plays a key role in regulating mitosis.5 To test
whether inhibition of survivin affects the cell cycle in
NSCLC cell lines, terameprocol-treated HCC2429 and H460
cells were fixed, stained with propidium iodide, and cell cycle
distribution determined using flow cytometry (Figure 4).
Neither 10 M nor 30 M terameprocol resulted in signifi-
cant alterations in the distribution of cells in G1, S, or G2
phases at either time point. These data suggest that mitotic
arrest does not play a significant role in the radiosensitization
of HCC2429 or H460 cells.
DISCUSSION
In this study, we have shown that terameprocol treat-
ment results in decreased transcription and expression of
survivin in HCC2429 and H460 lung cancer cell lines, though
this decrease was not shown to be associated with an increase
FIGURE 2. Radiation induces in-
creased cleaved caspase-3 in
HCC2429 cells but not H460 cells. A,
HCC24249 and H460 cells were irra-
diated with 3 Gy. The expression of
survivin, total caspase-3, and cleaved
caspase-3 in HCC2429 and H460
cell lysates was determined 0, 24,
48, and 72 hours after radiation
treatment by immunoblotting. Actin
was probed to demonstrate equal
loading. B, Immunoblotting was
used to determine the expression of
Bcl-2, Bcl-XL, Mcl-1, Bax, Bak, cIAP-1,
cIAP-2, XIAP, and survivin in
HCC2429 and H460 cell lysates. Tu-
bulin was probed to demonstrate
equal loading.
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in apoptosis. Nonetheless, terameprocol induces a significant
increase in the radiosensitization of both cell lines.
Terameprocol is an inhibitor of Sp1-mediated transcrip-
tion, and has been shown to decrease transcription and pro-
tein expression of several genes, including survivin and
CDK1.22,23 In this study, we have validated that terameprocol
effectively down-regulates transcription of survivin in both
HCC2429 and H460 cells. Interestingly, we found that sup-
pression of survivin transcription by terameprocol treatment
was greater in H460 cells compared with HCC2429 cells at
24 hours. Terameprocol treatment also induced decreased
survivin protein expression in a time- and dose-dependent
manner in both HCC2429 and H460 cell lines. Nevertheless,
subsequent data showed that although the terameprocol-in-
duced decrease in survivin transcription was greater in H460
cells, these results did not correlate with increased levels of
apoptosis relative to HCC2429 cells. Indeed, our data show
that only HCC2429 cells exhibited measurable levels of
apoptosis, despite a less profound down-regulation of sur-
vivin transcription after terameprocol treatment.
HCC2429 and H460 cell lines differ in their susceptibility
to apoptosis, as evidenced by their response to radiation.
HCC2429 cells expressed cleaved caspase-3, a marker for apo-
ptosis, in response to radiation treatment in a time-dependent
manner. H460 cells, however, showed no detectable levels of
cleaved caspase-3 at any time point. Notably, radiation resulted
in little to no change in survivin levels during the first 48 hours
of treatment. We have previously demonstrated that normal cells
will down-regulate survivin expression in response to radiation.
Malignant cells, however, fail to use this down-regulation.25,31
Our current data show that HCC2429 and H460 cells behave
similarly to other malignant cells in response to radiation, al-
though there is noticeable down-regulation of survivin protein
expression after 72 hours in both cell lines.
Because we saw a difference in levels of apoptosis be-
tween the two cell lines, the protein expression levels of anti-
apoptotic Bcl-2 family proteins (Bcl-2, Bcl-XL, and Mcl-1),
antiapoptotic XIAP family proteins (cIAP-1, cIAP-2, survivin,
and XIAP), and proapoptotic Bcl-2 family proteins (Bax and
Bak) were determined in both HCC2429 and H460 cell lines.
Overall, the levels of the antiapoptotic members of the Bcl-2
family were increased and the levels of proapoptotic members of
the Bcl-2 family were decreased in H460 cells relative to
HCC2429 cells. Expression of cIAP-1 and cIAP-2 was slightly
increased in HCC2429 cells compared with H460 cells, and both
cell lines showed high expression of XIAP and survivin. We
should note that H460 cells express wild-type p53, so the
mutational status of this gene does not explain the relative
resistance of this cell line to radiation. On the basis of these
results, we suggest that H460 cells have a greater block for
undergoing apoptosis because of their high expression of anti-
apoptotic Bcl-2 proteins and weak expression of proapoptotic
FIGURE 3. Terameprocol induces
increased radiosensitivity in
HCC2429 and H460 cells but en-
hances apoptosis in only HCC2429
cells when used with radiation. A,
HCC2429 and H460 cells were
treated with 10 M terameprocol or
dimethyl sulfoxide (DMSO) for 24
hours, followed by irradiation with 0
to 6 Gy at 1.8 Gy/min. Forty-eight
hours after irradiation, cells were cul-
tured in drug-free media and incu-
bated for 7 to 8 days. At this point,
the surviving fraction and the drug
enhancement ratio (DER) were de-
termined. Each experiment was per-
formed in triplicate, and data are
shown as mean  standard devia-
tion (SD). B, HCC2429 and H460
cells were treated with 10 M ter-
ameprocol or DMSO for 24 hours
followed by radiation treatment with
0 or 3 Gy. Expression of survivin,
total caspase-3, and cleaved
caspase-3 was determined by immu-
noblotting 48 hours postradiation
treatment. Actin was probed to
demonstrate equal loading.
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Bcl-2 members. One can speculate, therefore, that the differ-
ences in Bcl-2 family protein expression may contribute to the
observed resistance to radiation-induced apoptosis in the H460
cell line.
In this study, the administration of 10 M terameprocol
significantly enhanced the sensitivity of both HCC2429
(DER  1.26, p  0.019) and H460 (DER  1.18, p 
0.001) NSCLC cell lines to radiation treatment in clonogenic
assays. When survivin is inhibited, radiation results in in-
creased levels of apoptosis.27,30,32 This has previously been
demonstrated in H460 cells with the use of the small mole-
cule inhibitor YM15530 and antisense oligonucleotides.33
Nevertheless, survivin inhibition by terameprocol yields dif-
ferent results. The enhanced radiosensitization demonstrated
in both cell lines was only associated with an increase in
apoptosis in HCC2429 cells and not H460 cells, which
exhibited no measurable level of cleaved caspase-3. H460
cells again show a larger decrease in survivin expression after
radiation and terameprocol treatment, when compared with
HCC2429 cells, similar to data showing the effect of ter-
ameprocol treatment on survivin transcription levels in H460
cells (Figure 1A). Also, HCC2429 cells actually see an
increase in survivin expression with the combination
of terameprocol treatment and 3 Gy radiation compared with
terameprocol alone. This is especially puzzling because the
terameprocol and radiation combination induces increased
levels of cleaved caspase-3 relative to radiation alone. Thus,
apoptosis is occurring in HCC2429 cells even though sur-
vivin levels remain high. It can be suggested then that
terameprocol must exert effects not explained by survivin
levels alone. Mak et al.34 demonstrated a similar phenomenon
in leukemic cells. Administration of 0 to 40 M terameprocol
promoted cell death but failed to result in suppression of
survivin or Cdk1 expression.
Previous studies have shown that terameprocol induces
G2 cell cycle arrest by inhibiting expression of Cdk1 (Cdc2).22,35
Terameprocol may also induce G2 cell cycle arrest through
suppression of survivin levels, as survivin is a key regulator
of the mitotic spindle checkpoint along with INCENP and
Aurora Kinase B.28,36 Our data show, however, that ter-
ameprocol treatment did not induce any changes in cell cycle
distribution, including G2 arrest, in either HCC2429 or H460
FIGURE 4. Terameprocol treat-
ment does not induce cell cycle
changes in HCC2429 or H460 cells.
HCC2429 and H460 cells were cul-
tured with dimethyl sulfoxide
(DMSO), 10 M terameprocol, or
30 M terameprocol for 24 or 48
hours, followed by ethanol fixation
and staining with propidium io-
dide. Flow cytometry was used to
determine percentage of HCC2429
or H460 cells in G1, S, or G2
phases of the cell cycle. The analy-
sis was repeated three times using
flow cytometry and the data
graphed as a function of mean 
standard deviation (SD).
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cells relative to vehicle controls. These results suggest that G2
cell cycle arrest does not contribute to the increased radio-
sensitivity demonstrated in terameprocol-treated lung cancer
cell lines.
Terameprocol has been demonstrated to suppress survivin
and Cdk1 transcription by incorporating into GC-rich sequences
and interfering with the binding of the Sp1 protein to promoter
regions.37 Sp1 is ubiquitously expressed and has been shown to
regulate the expression of thousands of genes.38 As such, Sp1 is
implicated in nearly all facets of cellular function, including cell
growth, differentiation, apoptosis, and angiogenesis. It would be
extremely difficult to test the effect of terameprocol on the
expression of each Sp1-mediated gene and to determine each
gene’s role in radioresistance in NSCLC. Nevertheless, further
DNA and proteomic analysis may lend to our understanding of
the mechanism of action of terameprocol in enhanced radiosen-
sitization of lung cancer.
In conclusion, this study supports the potential of ter-
ameprocol as a radiosensitizing agent in lung cancer, although
the mechanism of action is unclear. Initial phase I clinical trials
have already shown that terameprocol is well tolerated and has
shown promising antitumor activity. Further study is needed to
assess the clinical efficacy of terameprocol as a drug that may
raise the therapeutic ratio of radiation therapy in lung cancer.
ACKNOWLEDGMENTS
Supported by NCI grant 1R01 CA125842-01A1.
The authors thank Lauren Mitchell for aiding in the
initial drafting of this manuscript.
REFERENCES
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer
J Clin 2009;59:225–249.
2. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res
2000;301:133–142.
3. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev
Cancer 2003;3:46–54.
4. Ryan BM, O’Donovan N, Duffy MJ. Survivin: a new target for anti-
cancer therapy. Cancer Treat Rev 2009;35:553–562.
5. Altieri DC. Targeted therapy by disabling crossroad signaling networks:
the survivin paradigm. Mol Cancer Ther 2006;5:478–482.
6. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits
apoptosis and promotes tumorigenesis. J Clin Invest 2004;114:1117–1127.
7. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP
by protein kinase A regulates cytoprotection. Mol Cell 2007;27:17–28.
8. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor
of survivin in apoptosis suppression. EMBO J 2003;22:2729–2740.
9. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene:
re-expression of survivin messenger RNA as a prognosis marker in
non-small-cell lung cancers. J Clin Oncol 1999;17:2100–2104.
10. Krepela E, Dankova P, Moravcikova E, et al. Increased expression of
inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell
lung carcinoma. Int J Oncol 2009;35:1449–1462.
11. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its
relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res
2000;6:127–134.
12. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by
survivin predicts shorter survival rates in colorectal cancer. Cancer Res
1998;58:5071–5074.
13. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated
with cancer cell apoptosis and is involved in the development of human
pancreatic duct cell tumors. Cancer 2001;92:271–278.
14. Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of
caspase cascade regulatory genes in adult T-cell leukaemia: survivin is
an important determinant for prognosis. Br J Haematol 2001;114:63–69.
15. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg
cells harbor alterations in the major tumor suppressor pathways and
cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;
101:681–689.
16. Kuttler F, Valnet-Rabier MB, Angonin R, et al. Relationship between
expression of genes involved in cell cycle control and apoptosis in
diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
Leukemia 2002;16:726–735.
17. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, sur-
vivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–921.
18. Asanuma K, Moriai R, Yajima T, et al. Survivin as a radioresistance
factor in pancreatic cancer. Jpn J Cancer Res 2000;91:1204–1209.
19. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of
endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99:
4349–4354.
20. Zaffaroni N, Daidone MG. Survivin expression and resistance to anti-
cancer treatments: perspectives for new therapeutic interventions. Drug
Resist Updat 2002;5:65–72.
21. Altieri DC. Survivin, versatile modulation of cell division and apoptosis
in cancer. Oncogene 2003;22:8581–8589.
22. Chang CC, Heller JD, Kuo J, et al. Tetra-O-methyl nordihydroguaiaretic
acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and
survivin expression. Proc Natl Acad Sci USA 2004;101:13239–13244.
23. Park R, Chang CC, Liang YC, et al. Systemic treatment with tetra-O-
methyl nordihydroguaiaretic acid suppresses the growth of human xeno-
graft tumors. Clin Cancer Res 2005;11:4601–4609.
24. Huang RC, Chang CC, Mold D. Survivin-dependent and -independent
pathways and the induction of cancer cell death by tetra-O-methyl
nordihydroguaiaretic acid. Semin Oncol 2006;33:479–485.
25. Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation
sensitization in lung cancer. Cancer Res 2004;64:2840–2845.
26. Kim KW, Mutter RW, Willey CD, et al. Inhibition of survivin and
aurora B kinase sensitizes mesothelioma cells by enhancing mitotic
arrests. Int J Radiat Oncol Biol Phys 2007;67:1519–1525.
27. Kami K, Doi R, Koizumi M, et al. Downregulation of survivin by siRNA
diminishes radioresistance of pancreatic cancer cells. Surgery 2005;138:
299–305.
28. Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of
mitosis and apoptosis and novel target for cancer therapeutics. Clin
Cancer Res 2008;14:5000–5005.
29. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-
molecule survivin suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res 2007;67:8014–
8021.
30. Iwasa T, Okamoto I, Suzuki M, et al. Radiosensitizing effect of YM155,
a novel small-molecule survivin suppressant, in non-small cell lung
cancer cell lines. Clin Cancer Res 2008;14:6496–6504.
31. Shinohara ET, Hallahan DE, Lu B. The use of antisense oligonucleotides
in evaluating survivin as a therapeutic target for radiation sensitization in
lung cancer. Biol Proced Online 2004;6:250–256.
32. Rodel F, Frey B, Leitmann W, et al. Survivin antisense oligonucleotides
effectively radiosensitize colorectal cancer cells in both tissue culture and
murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247–255.
33. Cao C, Mu Y, Hallahan DE, et al. XIAP and survivin as therapeutic
targets for radiation sensitization in preclinical models of lung cancer.
Oncogene 2004;23:7047–7052.
34. Mak DH, Schober WD, Chen W, et al. Tetra-O-methyl nordihydroguai-
aretic acid inhibits growth and induces death of leukemia cells indepen-
dent of Cdc2 and survivin. Leuk Lymphoma 2007;48:774–785.
35. Heller JD, Kuo J, Wu TC, et al. Tetra-O-methyl nordihydroguaiaretic
acid induces G2 arrest in mammalian cells and exhibits tumoricidal
activity in vivo. Cancer Res 2001;61:5499–5504.
36. Wheatley SP, Carvalho A, Vagnarelli P, et al. INCENP is required for
proper targeting of Survivin to the centromeres and the anaphase spindle
during mitosis. Curr Biol 2001;11:886–890.
37. Hwu JR, Tseng WN, Gnabre J, et al. Antiviral activities of methylated
nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhi-
bition of tat-regulated HIV transactivation. J Med Chem 1998;41:2994–
3000.
38. Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of
gene transcription. Mol Cell Biol 2009;29:2483–2488.
Sun et al. Journal of Thoracic Oncology • Volume 6, Number 1, January 2011
Copyright © 2010 by the International Association for the Study of Lung Cancer14
